| scholarly article | Q13442814 |
| P2093 | author name string | Thorp JM | |
| Stone MC | |||
| P2860 | cites work | Prevalence of hyperlipoproteinaemias in a random sample of men and in patients with ischaemic heart disease | Q36103919 |
| Plasma fibrinogen and plasminogen levels in health and in ischaemic heart disease | Q36520179 | ||
| A comparison of the erythrocyte sedimentation rate and plasma viscosity in detecting changes in plasma proteins | Q36608539 | ||
| Fibrin(ogen), platelets and a new theory of atherogenesis | Q37954827 | ||
| Erythrocyte-sedimentation rate before and after in-vitro defibrination: A rapid and simple method for increasing its specificity | Q39472647 | ||
| Risk factors for myocardial infarction in the Stockholm prospective study. A 14-year follow-up focussing on the role of plasma triglycerides and cholesterol | Q51663235 | ||
| Comparison of membrane filtration and nephelometry with analytical ultracentrifugation, for the quantitative analysis of low density lipoprotein fractions | Q53005711 | ||
| Relation between extent of coronary artery disease and blood viscosity. | Q54965703 | ||
| The fibrinogen-dependent pathway of platelet aggregation | Q70151754 | ||
| Fibrinogen as a risk factor for stroke and myocardial infarction | Q71438059 | ||
| Direct determination of plasma fibrinogen levels by heat precipitation. A comparison of the technique against thrombin clottable fibrinogen with spectrophotometry and radial immuno-diffusion | Q71541654 | ||
| Haemostatic function and cardiovascular death: early results of a prospective study | Q72423400 | ||
| Haemostatic factors in human aortic intima | Q72471293 | ||
| Hepatocyte-stimulating factor: a monocyte-derived acute-phase regulatory protein | Q72789255 | ||
| Coagulability of the blood in ischaemic heart-disease | Q74613964 | ||
| Simplified determination of the lipid components of blood serum | Q78825378 | ||
| Relation of plasma fibrinogen concentration changes to human arteriosclerosis | Q78972901 | ||
| P433 | issue | 281 | |
| P921 | main subject | risk factor | Q1475848 |
| P304 | page(s) | 565-569 | |
| P577 | publication date | 1985-12-01 | |
| P1433 | published in | The Journal of the Royal College of General Practitioners | Q26842074 |
| P1476 | title | Plasma fibrinogen--a major coronary risk factor | |
| P478 | volume | 35 |
| Q36268407 | 4G/5G polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome |
| Q68752290 | Acute changes in atherogenic and thrombogenic factors with cessation of smoking |
| Q35558976 | Association between job characteristics and plasma fibrinogen in a normal working population: a cross sectional analysis in referents of the SHEEP Study. Stockholm Heart Epidemiology Program |
| Q72759440 | Atherogenesis and fibrinogen: historical perspective and current status |
| Q44132801 | Changes in blood lipids and fibrinogen with a note on safety in a long term study on the effects of n-3 fatty acids in subjects receiving fish oil supplements and followed for seven years |
| Q39645453 | Comparison of an immunochemical assay for plasma fibrinogen and a turbidimetric thrombin clotting technique to discriminate hyperlipidaemic patients from healthy controls |
| Q33911689 | Control of fibrinogen biosynthesis: role of the FFA/albumin ratio |
| Q36682356 | Coronary heart disease in diabetes mellitus--antecedents and associations |
| Q36679823 | Corticosteroids: do they damage the cardiovascular system? |
| Q39513315 | Cyclic hormonal replacement therapy after the menopause: Transdermal versus oral treatment |
| Q42920767 | Dark nights behind the white clouds - risks of tobacco smoking on human health besides the oral health and malignancy |
| Q34107288 | Diet and hemostatic factors |
| Q33613250 | Does weight loss reduce plasma fibrinogen? |
| Q41875844 | Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients |
| Q33701658 | Ethnic differences in risk markers for heart disease in Bradford and implications for preventive strategies |
| Q34590944 | Evaluation of prothrombin time and activated partial thromboplastin time in hypertensive patients attending a tertiary hospital in calabar, Nigeria |
| Q28220294 | Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review |
| Q43162739 | Fibrinogen |
| Q35729527 | Fibrinogen and mechanisms of thrombosis. A difficult link |
| Q33612628 | Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study |
| Q41094038 | Fibrinogen levels and exercise. Is there a relationship? |
| Q42867792 | Fibrinogen: A new cardiovascular risk factor? |
| Q73295903 | Genetic Modulation of Plasma Fibrinogen Concentrations: Possible Importance of Interleukin-6 |
| Q35644256 | Genetic and environmental sources of fibrinogen variability in Israeli families: the Kibbutzim Family Study. |
| Q33594213 | Genetic variation at fibrinogen loci and plasma fibrinogen levels |
| Q34067819 | Haematology, ethnography, and thrombosis |
| Q42186702 | Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin |
| Q36682361 | Hypertension in non-insulin dependent diabetes mellitus and its management |
| Q34962142 | Hypertension, left ventricular hypertrophy, and sudden death |
| Q36896780 | Identification and treatment of risk factors for coronary heart disease in general practice: a possible screening model |
| Q41635547 | Influence of fibrinogen on cardiovascular disease |
| Q35576140 | Level of fibrinogen and risk of fatal and non-fatal stroke. EUROSTROKE: a collaborative study among research centres in Europe |
| Q49213720 | Longitudinal Impact of Smoking and Smoking Cessation on Inflammatory Markers of Cardiovascular Disease Risk |
| Q34140740 | Low-density lipoprotein apheresis in the treatment of atherosclerosis and other potential uses |
| Q41203672 | Modelling the Helsinki Heart Study by means of risk equations obtained from the PROCAM Study and the Framingham Heart Study |
| Q34086042 | Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms |
| Q38696278 | Orphan nuclear receptor ERRγ is a key regulator of human fibrinogen gene expression. |
| Q26796205 | Over 50 Years of Fibrinogen Concentrate |
| Q33740239 | Pathogenesis and pathology of coronary heart disease syndromes |
| Q41047260 | Plasma Concentration of Endogenous Tissue Plasminogen Activator and the Occurrence of Future Cardiovascular Events |
| Q35729514 | Plasma fibrinogen and factor VII as risk factors for cardiovascular disease |
| Q37296049 | Plasma fibrinogen, tissue plasminogen activator, plasminogen activator inhibitor 1, and their related factors in three Japanese population samples |
| Q35708776 | Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria |
| Q90291360 | Prognostic value of fibrinogen-to-albumin ratio in predicting 1-year clinical progression in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention |
| Q35168292 | Social influences and cardiovascular risk factors as determinants of plasma fibrinogen concentration in a general population sample of middle aged men. |
| Q41791338 | The association of combined alpha and beta fibrinogen genotype on plasma fibrinogen levels in smokers and non-smokers |
| Q34326163 | The biology behind the atherothrombotic effects of cigarette smoke |
| Q42979228 | Thrombin and plasmin activity in coronary artery disease |
| Q34409695 | Thrombotic vascular risk factors in inflammatory bowel disease |
| Q36854348 | Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery |
Search more.